Harvard doctor pinpoints make-up favourite that can make you go BLIND: 'Do not use'
Fake eyelashes could have devastating long-term health consequences—including blindness—a leading doctor has warned.
The adhesive used to apply them often contains a dangerous chemical, according to Dr Saurabh Sethi, a US-based doctor trained at Harvard University.
In a video posted to Instagram, which has racked up more than 120,000 views and over 1,000 likes, Dr Sethi explains the potential risks.
'Fake eyelashes are becoming increasingly popular, but the adhesive glue often contains formaldehyde, which can cause allergic reactions, thinning and permanent loss of natural eyelashes,' he says.
'In rare cases, it can even lead to blindness. To minimise this risk, avoid fake eyelashes or use formaldehyde-free adhesives.'
Experts say formaldehyde is added to lash glue to improve shelf life and stickiness—though the same chemical is more commonly used to preserve dead bodies.
At high concentrations, it can disrupt cellular function and trigger shortness of breath, headaches and skin irritation.
An American study from 2022 tested 37 lash glues and found that 75 per cent of the 20 professional products released formaldehyde, while four of the 17 consumer glues also contained the chemical.
Eyelash extensions are tiny, hair-like fibers that estheticians place under, between or on top of your natural lash line using glue to create long, luscious lashes
Some lash glues containing formaldehyde failed to list it among their ingredients.
The chemical can trigger a range of reactions when it comes into contact with the eye.
In a 2012 study by Japanese researchers involving 100 women who experienced adverse effects from fake eyelashes, 40 per cent were found to have had an allergic reaction to the glue.
The most common condition reported was keratoconjunctivitis—an inflammatory eye disorder affecting both the cornea and the conjunctiva.
The same study also found that some women developed blepharitis—an inflammation of the eyelids.
The eyelid margins contain hair follicles where lashes grow, along with two types of glands that produce antimicrobial substances to prevent bacterial buildup around the eyes.
Despite health warnings, the eyelash extension industry is booming.
Valued at $1.4 billion in 2020, it is projected to grow to $2.3 billion by 2028, according to Verified Market Research.
Eyelash extensions are tiny, hair-like fibres—typically made from synthetic materials, silk or mink—applied to the lash line using glue to create fuller, longer lashes.
The procedure is purely cosmetic and typically carried out by trained estheticians.
Interestingly, scientists have recently uncovered the biological function of eyelashes.
A 2023 study by researchers in China found that lashes play a crucial role in protecting the eyes—from diverting sweat and water, to reducing airflow over the eye's surface, keeping it lubricated and shielding it from airborne particles by triggering blinking.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
40 minutes ago
- Telegraph
This firm represents one of investing's toughest moral debates
While many big drug companies do amazing things for humanity, they're also often vilified for profiteering from their work. This month, New York-listed Gilead Sciences has, not for the first time, reminded investors of the conundrum. On June 18, Gilead announced it had gained approval from the US regulator for a treatment that some view as having the potential to end the global 'HIV epidemic'. At the same time, it has drawn criticism in anticipation of US prices being set at more than $28,000 (£20,400) per patient, per year. Lenacapavir, to be marketed by Gilead under the name Yeztugo, is a twice-yearly injection that prevents people from contracting HIV. This has the potential to disrupt the market for preventative HIV drugs, which is currently dominated by another Gilead treatment, a daily pill named Descovy. Financially, Gilead hopes to gain from lenacapavir by expanding the market for preventative HIV treatments. It also could benefit from existing users of Descovy switching to the somewhat more expensive new treatment, and people switching from other long-lasting preventatives such as GSK's bi-monthly Apretude. The breakthrough is important in strengthening Gilead's HIV franchise more broadly, too. HIV drugs accounted for almost 70pc of product sales last year, and year-on-year growth of HIV-related revenues came in at 8pc in the first quarter. The group's single biggest-selling drug is Biktarvy, a treatment for people who are already HIV positive. The daily oral pill generates around $13.4bn of sales, or 47pc of the group total. Gilead is currently leveraging its research into lenacapavir by attempting to develop a twice-yearly treatment in this space, too. Gilead's major drug breakthroughs have not always proved as rewarding for shareholders as they have for patients. Covid-19 sent the shares on a roller-coaster ride after one of Gilead's hepatitis C treatments, called Remdesivir, was originally found to also be very effective against the coronavirus. Sales of the drug, rebranded Veklury, hit $5.6bn in 2021 but rapidly fell as the pandemic eased, and revenues are expected to be just $1.3bn this year. An earlier breakthrough in the treatment of hepatitis C in the 2010s, meanwhile, caused huge share price excitement, with revenues ballooning to nearly $14bn in 2015 before the drug became a victim of its own success. Because the drug, called Harvoni, found a way to cure the disease as opposed to managing it, it did away with much of its own market. Rising competition also contributed to a rapid decline in sales. However, many top investors are more bullish on the lenacapavir breakthrough. Financial publisher Citywire, which tracks where the world's best fund managers are investing, has found 12 backing the shares – all among the best-performing 3pc of equity managers globally. The level of these bets puts Gilead among the 74 stocks that make up Citywire's Global Elite Companies index, which represents the very best ideas from the roughly 6,000 stocks held across the portfolios of top fund managers. Optimism about Gilead's prospects can be seen in its share price, too. The valuation against forecast earnings is within the top 5pc of the 10-year range. While in some circumstances this would be grounds to worry about the shares being expensive, the fact Gilead is only valued at 13 times forecast earnings makes it is more a reason to take heart than worry. Indeed, the uninspiring valuations of previous years reflect the ups and downs associated with Veklury and Harvoni. Today, the future looks much brighter. Sales of Veklury appear to be stabilising and now represent a relatively small proportion of the business. Meanwhile, as well as the strong HIV franchise, the company is experiencing solid growth in cancer and liver disease treatments. The drug development pipeline also looks strong, and is supported by about a fifth of sales going into research and development (R&D) each year. The group also does not face any major loss of patents until 2033. Meanwhile, attempts to drive down operating costs are benefiting the bottom line. The good progress has been reflected in analysts raising their earnings forecasts over the last 12 months. Expectations for the current year and next are both up by more than 10pc over the period, and while there is some downward pressure on revenue from US drug pricing policies, Gilead looks relatively well placed due to its focus on novel medicines. Its extensive US operations also reduce the threat from tariffs. The shares offer an attractive 3pc forecast dividend yield, and the company has a strong track record for returning cash. British buyers of the shares, which are available through all the big broking platforms, need to fill out the current paperwork to minimise withholding tax and should also check for any extra dealing charges. While walking the tightrope between profit and purpose is never easy, as an investment, Gilead looks better placed than it has for quite some time. Questor says buy Ticker: NYSE:GILD
Daily Mail
an hour ago
- Daily Mail
EXCLUSIVE I died and came back after being shown the true meaning of life... everything you've been taught is wrong
A lawyer and devout Catholic grew up believing life and death were black and white until an extraordinary experience changed her entire view of the universe. During a near-death experience, Nanci Danison of Ohio said she received an astonishing revelation that everything in existence is part of an energy source that incarnates inside humans as what we call souls.
BBC News
2 hours ago
- BBC News
Thornton families' cancer fears in shadow of 'forever chemical' plant
Stephen Copson had always looked after himself, water-skiing on the River Wyre in Lancashire in his 20s and trying to eat healthily by growing his own vegetables in his in 2016, his life changed for ever when he was diagnosed with aggressive prostate cancer, and since then has had five different cancer Copson, now 72, does not know what caused his cancers, and an expert told the BBC there was no way to link a specific substance to a cancer in an individual. But the possibility that living close to a huge chemical plant was in some way to blame is never far from Mr Copson's year he was one of about 6,000 people who were advised by the Environment Agency not to eat fruit and vegetables grown in the local soil over concerns about the levels of a potentially carcinogenic substance in the ground near to the AGC Chemicals Europe plant in Chemicals Europe – which bought the plant from ICI – said it had stopped using Perfluoroalkyl and Perfluorooctanoic acid (PFOA) in 2012, and that 40 years of monitoring showed no "significant impact" from District Council said it cannot be certain of any links with ill-health, and had "advised a 'better safe than sorry' approach to eating home grown produce". Cancer rates in the neighbourhood are broadly in line with those in surrounding areas. But retired kitchens salesman Mr Copson said he feared years of eating his own fruit and vegetables and using the River Wyre might have been a factor in his medical problems."I water-skied on the Wyre past the ICI sites in my 20s, grew all my own vegetables, and it just makes you think, was that contributory?" he said. Forever Chemicals The Hillhouse chemical site had been using PFOA since the as "forever chemicals", they are indestructible and do not dissolve or are resistant to water, oil and heat and have become popular in manufacturing products such as non-stick pans, waterproof clothing and fire-fighting acid (PFOA) was banned in 2020 by the European Union and declared hazardous to human and environmental health. It was classed as a carcinogen in 2023 by the International Agency for Research on Cancer (IARC), the cancer agency of the World Health Organization (WHO).Rachel Salvidge, a journalist-campaigner with Watershed Investigations, which looks into pollution in waterways, first uncovered signs of contamination in the Thornton-Cleveleys area over two years ago."We walked along the River Wyre and saw discharge from the site flowing directly into the water," she said."We took samples and were shocked to find PFOA at concentrations of 12,000 nanograms per litre—an alarmingly high level for a banned substance.""We were stunned to find a known carcinogen just flowing straight into the water," she added. A joint investigation by Wyre District Council and the Environment Agency did tests in 2024. Twenty-two areas of public land within 5km (3.1 miles) were tested and the highest concentration of PFOA was 25 times above the Environment Agency's screening of those zones lies behind Mr Copson's house."It's just a stone's throw away," said Mr Copson, who has lived in Thornton-Cleveleys all his life."I can throw a tennis ball from my house onto the ground [that has been tested]," he said. "It means if that's contaminated, all this area will be contaminated, too."The BBC has spoken to four other people in the area who all told the BBC they were worried their illnesses might have been connected to PFOA. Cancer rates The Thornton area is not the only one in the British Isles were there are concerns about the impact of 2024, residents in Bentham, North Yorkshire, launched legal proceedings against a firefighting foam manufacturer over potential health risks caused by the chemicals, while in April, scientists advising the Jersey government recommended that anyone exposed to PFAS should be offered of cancer in Lancashire are broadly similar to those of other parts of the north-west of England, which is 8% above the national average, according to a report by North West Cancer Research published last to Lancashire County Council's data covering the five years up to 2022/2023, the percentage of people reporting cancer across Lancashire and the south of the Lake District was 3.5%, "similar to England (3.2%)".Figures for the Thornton area, compiled from NHS data by the Ribble Rivers Trust, showed that in 2021 the estimated number of people with cancer was 411 – 4.49% of the 9,152 Thornton West the number was 439 (4.58% of 9,558) and in Thornton-Cleveleys, it was 337 (4.42% of 7,614).Neighbouring areas' cancer rates were broadly in line with those of David Megson, an expert in environmental forensics, said it was not possible to definitively link exposure to a specific substance from a specific source with cancer in one said: "There are many potential causes of cancer, and someone can be exposed to chemical pollution through multiple pathways."He said that making the case for a pollutant having caused illness required investigating concentrations of the substance in a person to see if it was elevated when compared with other people, and to see whether rates of illness where higher close to a specific source, compared with elsewhere."We can also perform chemical fingerprinting to see if the chemical mixture present in an individual matches the chemical mixture from a suspected pollution source. These investigations can take years as they are incredibly complex and challenging, not only from a scientific perspective but for the individuals involved," he added. Other people who were not ill said the worry about possible exposure to contaminates still loomed large. After the initial warning about locally grown food was issued by Wyre District Council, it undertook further tests, including on community results showed that beetroot, kale, cabbage and chard were among the crops to contain PFOA. The maximum level found in soil samples was 20.2 microgrammes per kg, "exceeding the precautionary screening value of 1.4 microgrammes per kg".Retired David Thompson said he had grown his own food on an allotment for the past seven years."I'm coming up 74, and I know I'm at the tail end of the cricket match. But I don't want to finish up with something that I've inadvertently caused myself," he said. 'Rigorously monitored' AGC Chemicals Europe said it "was expected that any PFOA in the current effluent discharge is related to historical emissions and environmental background levels".A spokesperson added that no investigation had "yet established whether the levels of PFOA in the soil near to the site are sufficient to create a significant risk to human health, or the extent to which background conditions from other potential sources have contributed to elevated levels".The spokesperson added: "These issues will be addressed as the investigation continues, and more research is conducted."Many of us – as well as former employees – live locally. We appreciate people's concerns and frustrations that some critical questions cannot yet be answered, and we are doing everything we can to assist the multi-agency investigation."The company said all its chemical processes were "rigorously monitored and controlled and compliant with current UK and EU environmental laws and regulations", and that the firm took its responsibilities to protect environmental health "extremely seriously".A Wyre District Council spokesman said: "We fully appreciate the worry and concern the ongoing investigation will cause to residents in the local area."The safety and wellbeing of our residents is paramount and we are therefore doing all that we can to make sure this complex process moves forward without delay, while crucially allowing it to be carried out thoroughly and with enough time for the analysis provided by expert scientists to be considered robust and conclusive."As a council, we have no remit in relation to health, and we therefore continue to urge UK Health Security Agency and Lancashire County Council to provide expert assessment, advice and expertise to the community at the earliest point."Ultimately, it is the role of these agencies to assess what level of risk to human health, if any, is present in the local area and to take action where appropriate – something we will push for on behalf of our residents."In the meantime, we have shared precautionary 'better safe than sorry' advice with the community at the earliest point in relation to the consumption of home grown produce. We have done this to give people the opportunity to make an informed decision until more information comes forward from the relevant health agencies and organisations."Wyre District Council is currently doing its second stage of testing with the Environment agency, sampling residential gardens in the area. It said it hoped to release the results in the summer. Additional research by Scott Hesketh and Will HiggensAre you affected by this story? Contact Hayley Hassall at Listen to the best of BBC Radio Lancashire on Sounds and follow BBC Lancashire on Facebook, X and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
